PMID: 7580551Oct 7, 1995Paper

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group

BMJ : British Medical Journal
M BrautigamG Weidinger

Abstract

To compare the efficacy and tolerability of terbinafine and itraconazole in the treatment of toenail tinea unguium. Multicentre, double blind, parallel group study. 17 university hospitals, one army hospital, and five dermatology practices. 195 patients with clinically suspected toenail tinea and growth of dermatophytes in baseline culture; data on 86 patients in the terbinafine group and 84 patients in the itraconazole group were fully evaluated for efficacy. Daily dose of 250 mg terbinafine or 200 mg itraconazole for 12 weeks, with follow up for a further 40 weeks. Mycological cure (negative results on microscopy and culture) and clinical improvement (length and area of unaffected nail) at week 52 or at discontinuation of treatment. At the end of the study mycological cure rates were 81% (70 out of 86) for terbinafine and 63% (53 out of 84) for itraconazole (2P < 0.01). Negative culture was achieved in 92% (79 out of 86) in the terbinafine group and 67% (56 out of 84) in the itraconazole group (2P < 0.0001). Length of unaffected nail was 9.44 mm in the terbinafine group and 7.85 mm in the itraconazole group (2P < 0.05). Terbinafine is more effective than itraconazole in the treatment of toenail tinea infection.

References

May 1, 1992·Journal of the American Academy of Dermatology·M WillemsenD Roseeuw
Feb 1, 1992·The British Journal of Dermatology·J G van der SchroeffJ Wuite
Feb 1, 1992·The British Journal of Dermatology·F Baudraz-RosseletR Kenzelmann
Feb 1, 1995·International Journal of Dermatology·R ArenasL M Fernández
Jul 3, 1993·BMJ : British Medical Journal·M BeutlerJ Gartmann

❮ Previous
Next ❯

Citations

Jun 1, 1996·The British Journal of Dermatology·R NandwaniD A Hawkins
Jul 22, 2005·International Journal of Clinical Practice·S H Wang, C C Chi
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Dec 12, 2001·PharmacoEconomics·V N Joish, E P Armstrong
Aug 11, 2004·American Journal of Clinical Dermatology·Aditya K GuptaMaria M Chaudhry
Nov 3, 2007·Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·Hideomi Shibaki
Dec 20, 2013·American Journal of Clinical Dermatology·Daniel Coelho de SáAntonella Tosti
Jul 1, 1996·Clinical Therapeutics·A MarchettiB T Smith
Feb 3, 1996·BMJ : British Medical Journal·D S Buck
Oct 17, 1998·BMJ : British Medical Journal·M BräutigamS Nolting
Feb 28, 2004·BMJ : British Medical Journal·Geert W 't JongMiriam C J M Sturkenboom
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Jason G Newland, Susan M Abdel-Rahman
Feb 10, 2006·The Journal of Dermatological Treatment·Bardur SigurgeirssonRajesh Bakshi
Aug 1, 1998·The Physician and Sportsmedicine·M P Seraly, M L Fuerst
Jan 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A K Gupta, N H Shear
Apr 29, 2003·Journal of the American Academy of Nurse Practitioners·Ellen Davis Jones
Sep 4, 2007·The American Journal of Medicine·Chia-Hsuin ChangArnold K Chan
May 22, 1998·Journal of the American Academy of Dermatology·M Bräutigam
May 22, 1998·Journal of the American Academy of Dermatology·J L Bootman
Jan 1, 1997·Dermatologic Clinics·A K GuptaP De Doncker
Apr 5, 2016·The Journal of Dermatological Treatment·Aditya K Gupta, Catherine Studholme
Feb 14, 2016·Journal of Pharmacy Practice·Mara PoulakosErin Dorval
Mar 17, 2004·Dermatologic Clinics·Daniel S Loo
Aug 19, 2005·Expert Review of Anti-infective Therapy·Adolfo C Fernandez-ObregonCarolyn Willis
Mar 26, 2003·The British Journal of Dermatology·D T RobertsUNKNOWN British Association of Dermatologists
Jan 19, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Claus SeebacherHans-Jörgen Tietz
Mar 13, 1998·The Annals of Pharmacotherapy·E F Trépanier, G W Amsden
Jun 18, 2016·Journal of Cutaneous Medicine and Surgery·Aditya K GuptaKelly A Foley
Sep 29, 2017·Journal of Cutaneous Medicine and Surgery·Aditya K GuptaNeil H Shear
Aug 12, 2000·International Journal of Dermatology·A K GuptaH Degreef
Oct 9, 1999·International Journal of Dermatology·J E ArreseG E Piérard
Oct 9, 1999·International Journal of Dermatology·A K Gupta, J Lambert
Mar 24, 2000·The British Journal of Dermatology·D T Roberts
Mar 24, 2000·The British Journal of Dermatology·C De Cuyper, P H Hindryckx
Dec 3, 1999·The British Journal of Dermatology·M J Goodfield, E G Evans
Jun 16, 1999·International Journal of Dermatology·S BillsteinA Justice
Jan 29, 2000·International Journal of Dermatology·S Jain, V N Sehgal
Aug 16, 2000·International Journal of Dermatology·S Jain, V N Sehgal
Jul 9, 2002·The British Journal of Dermatology·M HaughB J Cribier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.